Background: Sodium-glucose transporter 2 inhibitors (SGLT2i) are widely used for diabetes management and have demonstrated benefits in treating acute and chronic heart failure (HF) and chronic kidney disease (CKD). Their increasing application has revealed various side effects, although only a few are currently recognized as drug-related adverse events, based on ongoing observations. Aims: This review synthesizes positive and negative side effects linked to SGLT2i and proposes management strategies. Methods: A literature search of PubMed/EMBASE, Web of Science, and Google Scholar from the past 10 years identified randomized trials, meta-analyses, observational cohorts, and pharmacovigilance studies reporting SGLT2i-related events across genitourinary, endocrine, metabolic, hematologic, skeletal, and vascular domains. Results: Data indicate an increased incidence of genital infections (GIs) in diabetic subjects, while associations with urinary tract infections (UTIs) are less consistent. Non-diabetic HF/CKD patients show modest increases in GIs and UTIs. SGLT2i modestly increase hematocrit and may reveal clonal erythrocytosis. Rare conditions like Fournier’s gangrene have been reported, though without a clearly increased risk in clinical trials: all the reported cases led to drug discontinuation. There is no conclusive evidence linking SGLT2i to fractures or osteoporosis, and risk of lower-limb amputation appears comparable to DPP-4 inhibitors, with some trend compared to GLP-1 receptor agonists, suggesting caution in patients with peripheral artery disease. Observational data suggest SGLT2i may protect against syncope and reduce acute kidney injury. Conclusions: Overall, SGLT2i are safe, with manageable adverse events such as GIs and UTIs. A thorough understanding of potential complications is essential for clinicians to optimize patients’ management.

Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors / Falsetti, L., Tarquinio, N., Mucci, L., Santini, S., Guerrieri, E., Giovenali, L., Pierdomenico, G., Zaccone, V., Viticchi, G., Moroncini, G.. - In: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0031-6970. - ELETTRONICO. - 82:4(2026). [10.1007/s00228-026-04023-9]

Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors

Falsetti L.
Primo
Writing – Original Draft Preparation
;
Tarquinio N.
Writing – Original Draft Preparation
;
Mucci L.
Writing – Original Draft Preparation
;
Santini S.
Writing – Original Draft Preparation
;
Guerrieri E.
Writing – Original Draft Preparation
;
Giovenali L.
Writing – Original Draft Preparation
;
Pierdomenico G.
Writing – Original Draft Preparation
;
Zaccone V.
Writing – Review & Editing
;
Viticchi G.
Writing – Review & Editing
;
Moroncini G.
Writing – Review & Editing
2026-01-01

Abstract

Background: Sodium-glucose transporter 2 inhibitors (SGLT2i) are widely used for diabetes management and have demonstrated benefits in treating acute and chronic heart failure (HF) and chronic kidney disease (CKD). Their increasing application has revealed various side effects, although only a few are currently recognized as drug-related adverse events, based on ongoing observations. Aims: This review synthesizes positive and negative side effects linked to SGLT2i and proposes management strategies. Methods: A literature search of PubMed/EMBASE, Web of Science, and Google Scholar from the past 10 years identified randomized trials, meta-analyses, observational cohorts, and pharmacovigilance studies reporting SGLT2i-related events across genitourinary, endocrine, metabolic, hematologic, skeletal, and vascular domains. Results: Data indicate an increased incidence of genital infections (GIs) in diabetic subjects, while associations with urinary tract infections (UTIs) are less consistent. Non-diabetic HF/CKD patients show modest increases in GIs and UTIs. SGLT2i modestly increase hematocrit and may reveal clonal erythrocytosis. Rare conditions like Fournier’s gangrene have been reported, though without a clearly increased risk in clinical trials: all the reported cases led to drug discontinuation. There is no conclusive evidence linking SGLT2i to fractures or osteoporosis, and risk of lower-limb amputation appears comparable to DPP-4 inhibitors, with some trend compared to GLP-1 receptor agonists, suggesting caution in patients with peripheral artery disease. Observational data suggest SGLT2i may protect against syncope and reduce acute kidney injury. Conclusions: Overall, SGLT2i are safe, with manageable adverse events such as GIs and UTIs. A thorough understanding of potential complications is essential for clinicians to optimize patients’ management.
2026
Acute kidney injury; Adverse events; Amputation; Chronic kidney disease; Erythrocytosis; Fractures; Genitourinary infections; Heart failure; Ketoacidosis; SGLT2 inhibitors
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/367177
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact